|Bid||0.0000 x 1400|
|Ask||0.0000 x 800|
|Day's Range||4.5900 - 4.7000|
|52 Week Range||3.2500 - 5.6500|
|Beta (3Y Monthly)||1.69|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
A look at the shareholders of MTBC, Inc. (NASDAQ:MTBC) can tell us which group is most powerful. Insiders often own a...
MTBC, Inc (MTBC) reported financial results for their first quarter 2019 and provided a business update. As a reminder, financial performance immediately benefitted from the transaction, which included revenue setting record highs in Q3 and two of the three acquired business segments, namely Practice Management and the GPO, adding to profitability in that period. Particularly noteworthy (given that this metric is used to value EHR / RCM companies) is that adjusted EBITDA came in at the third best in history in Q4’18 and at an all-time high in Q1’19.
MTBC, Inc. (MTBC) reported financial results for their fourth quarter 2018 and provided a business update. Financial performance immediately benefitted from the transaction, which included revenue setting record highs in Q3 and two of the three acquired business segments, namely Practice Management and the GPO, adding to profitability in that period. Meanwhile, their initial 2019 guidance for revenue growth of at least 20%, which was announced in a January 2019 shareholder letter, has already been adjusted – to growth between 25% and 29%.
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be remiss not to mention that insider sales have Read More...
Accumulation is close to an all-time high, signaling strong speculative interest. A cup and handle breakout would yield an impressive measured move target near $9.50, which is close to a 2015 breakdown into single digits.
Medical Transcription Billing Corp (MTBC) reported financial results for their third quarter 2018 and provided a business update. Financial performance is already benefitting from the transaction with Q3 setting new record highs in revenue, revenue growth and consecutive quarters (i.e.
Penny stocks got battered and bruised during the month of October, undermined by a broad-based retreat that dropped the Russell 2000 small-cap index to an eight-month low. The broad market could post new lows in early November, but a profitable relief rally should unfold in coming weeks, favoring dip trades on penny stocks that have held technical support levels through the maelstrom. This month's penny stock list includes several of these plays, but it's important to think and act defensively, placing stop losses immediately after entry. Penny Stock Picks to Buy Using Technical Analysis for November 1.
If you’re interested in Medical Transcription Billing Corp (NASDAQ:MTBC), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock Read More...
Blue chips led broad price action in September, lifting the S&P 500 and the Dow Jones Industrial Average to bull market highs while small cap indices such as the Russell 2000 pulled back in shallow declines. Penny and low-priced stocks held up well during the month despite this headwind, with traders scooping up junior energy plays in reaction to a surging crude oil market. Penny stock buyers have taken notice, lifting the shares of low-priced American oil and gas companies still reeling from the group's historic decline into 2016.
Penny stocks approaching key price levels dominate September's technical analysis buy list, telling interested traders to build watch lists and track progress while awaiting fruitful buying signals or reversals that break bullish patterns. First, establish the price level that is likely to attract strong buying interest. Second, look for the price level that is likely to attract strong selling interest.
This upwardly revised guidance is well ahead of the $42.3M in revenue and $3.6M in adjusted EBITDA that we had been modeling for 2018 following the announced-close of the Orion acquisition in early July. Updates to our model have resulted in calculated fair value of MTBC common stock moving from $7.10/share (previously) to $10.0/share (currently). In fact, excluding Q4 ’16 which benefitted from one-time sales following close of the MediGain acquisition, Q1 and Q2 2018 set new quarterly revenue records.